Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of ALXN2050 in lupus nephritis and IgA nephropathy
2021-001426-22Phase 2Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) and IgA nephropathy (IgAN) comparing ALXN2050 dose-finding arm(s) with Placebo arm (2 arms). Primary endpoint: Percentage change in proteinuria (primary). Started Nov 2021; status: active.
02
Drugs
vemircopan
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2021-001426-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001426-22.